Nunzia Pharmaceutical Stock Cash And Equivalents
| NUNZ Stock | USD 0 0.00 0.00% |
Nunzia Pharmaceutical fundamentals help investors to digest information that contributes to Nunzia Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Nunzia Pink Sheet. The fundamental analysis module provides a way to measure Nunzia Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nunzia Pharmaceutical pink sheet.
Nunzia |
Nunzia Pharmaceutical Company Cash And Equivalents Analysis
Nunzia Pharmaceutical's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Nunzia Pharmaceutical Cash And Equivalents | 5.07 K |
Most of Nunzia Pharmaceutical's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nunzia Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Nunzia Pharmaceutical has 5.07 K in Cash And Equivalents. This is 100.0% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
Nunzia Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nunzia Pharmaceutical's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Nunzia Pharmaceutical could also be used in its relative valuation, which is a method of valuing Nunzia Pharmaceutical by comparing valuation metrics of similar companies.Nunzia Pharmaceutical is currently under evaluation in cash and equivalents category among its peers.
Nunzia Fundamentals
| Return On Asset | -2702.39 | |||
| Current Valuation | 87.59 M | |||
| Shares Outstanding | 434.52 M | |||
| Shares Owned By Insiders | 81.95 % | |||
| EBITDA | (9.02 M) | |||
| Net Income | (9.02 M) | |||
| Cash And Equivalents | 5.07 K | |||
| Total Debt | 139.96 K | |||
| Current Ratio | 0.20 X | |||
| Cash Flow From Operations | (86.78 K) | |||
| Earnings Per Share | (0.28) X | |||
| Beta | -2.57 | |||
| Market Capitalization | 24.88 M | |||
| Total Asset | 5.13 K | |||
| Net Asset | 5.13 K |
About Nunzia Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nunzia Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nunzia Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nunzia Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Nunzia Pink Sheet Analysis
When running Nunzia Pharmaceutical's price analysis, check to measure Nunzia Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nunzia Pharmaceutical is operating at the current time. Most of Nunzia Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Nunzia Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nunzia Pharmaceutical's price. Additionally, you may evaluate how the addition of Nunzia Pharmaceutical to your portfolios can decrease your overall portfolio volatility.